Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 15, Pages 3704
Publisher
MDPI AG
Online
2021-07-23
DOI
10.3390/cancers13153704
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
- (2021) Agnieszka Rybarczyk-Kasiuchnicz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutic Sequencing in ALK+ NSCLC
- (2021) Mei Elsayed et al. Pharmaceuticals
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
- (2021) Cheng-Hao Chuang et al. Cancers
- Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis
- (2021) Lida Wang et al. JOURNAL OF CHEMOTHERAPY
- Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers
- (2020) Aaron C. Tan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
- (2020) Jesse Elliott et al. PLoS One
- Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
- (2020) Tung Hoang et al. Cancers
- Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
- (2020) Joan Rou-En Choo et al. Expert Review of Anticancer Therapy
- Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
- (2020) Koichi Ando et al. Cancers
- Systemic treatment of brain metastases in non-small cell lung cancer
- (2020) Simon Page et al. EUROPEAN JOURNAL OF CANCER
- Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer
- (2020) Haidar El Darsa et al. EXPERT OPINION ON PHARMACOTHERAPY
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
- (2020) Valerio Gristina et al. Pharmaceuticals
- Lorlatinib: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
- (2019) Koutaroh Okada et al. EBioMedicine
- Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
- (2019) Arthur Aubry et al. Cancers
- Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials
- (2019) Yen-Chien Lee et al. Medicina-Lithuania
- The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
- (2019) Hiroaki Akamatsu et al. International Journal of Clinical Oncology
- Lung Cancer
- (2019) Faria Nasim et al. MEDICAL CLINICS OF NORTH AMERICA
- Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis
- (2019) Zhiguo Zhang et al. Journal of Thoracic Disease
- Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
- (2019) Caicun Zhou et al. Lancet Respiratory Medicine
- The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
- (2019) Stephen P. Ducray et al. Cancers
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Alectinib: A Review in Advanced, ALK-Positive NSCLC
- (2018) Julia Paik et al. DRUGS
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
- (2018) Jessica J. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
- (2018) Yi-Long Wu et al. Journal of Thoracic Oncology
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
- (2018) Junsheng Fan et al. Cancer Medicine
- Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
- (2018) Anna Wrona et al. CANCER TREATMENT REVIEWS
- Receptor Tyrosine Kinase-Targeted Cancer Therapy
- (2018) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
- (2017) Joshua K Sabari et al. OncoTargets and Therapy
- Emerging treatment for ALK-positive lung cancer
- (2016) Janaki Sharma et al. EXPERT OPINION ON EMERGING DRUGS
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Alectinib for ALK-positive non-small-cell lung cancer
- (2016) Antonio Rossi Expert Review of Clinical Pharmacology
- The PRISMA Extension for Network Meta-analysis: Bringing Clarity and Guidance to the Reporting of Systematic Reviews Incorporating Network Meta-analyses
- (2015) John E. Cornell ANNALS OF INTERNAL MEDICINE
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
- (2015) Hideko Isozaki et al. CANCER RESEARCH
- New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer
- (2015) Laird Cameron et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
- (2015) Isabella Zhang et al. LANCET ONCOLOGY
- ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
- (2015) Ivana Sullivan et al. Therapeutic Advances in Medical Oncology
- Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
- (2014) Kate McKeage DRUGS
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- Evidence Synthesis for Decision Making 3
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Evidence Synthesis for Decision Making 4
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Evidence Synthesis for Decision Making 2
- (2012) Sofia Dias et al. MEDICAL DECISION MAKING
- Meta-analysis and sensitivity analysis for multi-arm trials with selection bias
- (2011) Hathaikan Chootrakool et al. STATISTICS IN MEDICINE
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
- (2011) Jeroen P. Jansen et al. VALUE IN HEALTH
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
- (2010) Georgia Salanti et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons
- (2008) Jeroen P. Jansen et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started